Renovacor will present at the 5th annual virtual conference of genetic medicine in Chardan


PHILADELPHIA CREAM – (COMMERCIAL THREAD) – Renovacor, Inc. (NYSE: RCOR), a biotechnology company developing adeno-associated virus (AAV) gene therapies for devastating diseases of the cardiovascular system and central nervous system resulting from BAG3 genetic variants, announced today that CEO Magdalene Cook, MD will participate in a fireside conversation at Chardan Virtual 5e Annual Genetic Drugs Conference Tuesday, October 5, 2021 at 11:30 a.m. EDT.

A webcast of the Fireside Chat will be available by visiting the Investors and Media section of the Renovacor website under “Events and Presentations”. A replay of the webcast will be available on the Renovacor website for 30 days after the conference.

About Rénovacor

Renovacor is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 diseases associated with gene mutations in areas with high unmet medical needs. The therapeutic orientation of Renovacor is initially focused on cardiovascular diseases, with a program of BAG3 dilated cardiomyopathy associated with a mutation. For more information, please visit www.renovacor.com. No part of the Renovacor website is incorporated by reference or otherwise considered to be part of this press release.

Forward-looking statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the anticipated development of Renovacor’s product candidates. These forward-looking statements are generally identified by the words “believe”, “plan”, “expect”, “anticipate”, “estimate”, “intend”, “the strategy”, “the future”, “The opportunity”, “the plan,” “may”, “should”, “will”, “would”, “will”, “will continue”, “will probably result” and similar expressions. Forward-looking statements are predictions, projections and other statements regarding future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements contained in this press release. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of Renovacor’s proxy circular / definitive disclosure statement dated August 4, 2021 and other documents filed by Renovacor from time to time with the Securities Exchange Commission. These documents identify and discuss important risks and uncertainties that could cause actual events and results to differ materially from those contained in forward-looking statements. Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and Renovacor assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Renovacor gives no assurance that it will meet its expectations.


Source link

Previous Open banking, BNPL and banking transformation
Next Gabby Petitio news - latest: live updates from Brian Laundrie as the Petito family hold a press conference

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *